How to prevent allergic reactions to paclitaxel in the treatment of ovarian cancer

In clinical practice, paclitaxel can be used for chemotherapy of ovarian cancer. Some patients may have allergic reactions to paclitaxel, which not only brings pain to patients but also increases the difficulty of treatment. So, how to prevent allergic reactions to paclitaxel in the treatment of ovarian cancer?

1. The incidence of allergic reactions can reach more than 30%. Even a very small dose of paclitaxel can cause hypersensitivity reactions in patients. Symptoms of mild allergic reactions include skin flushing and urticaria, while severe allergic reactions may manifest as bronchospasm, dyspnea, hypotension, and even shock and angioneurotic edema. All allergic reactions can occur within 10 minutes of medication, so they should be prevented in time. The incidence of allergic reactions can be significantly reduced by changing the dosage form of the drug and improving the method of administration.

2. To prevent allergic reactions, patients can use anti-allergic drugs prophylactically before medication.

3. Oxygen, electrocardiogram, first aid medicines, etc. should be prepared before taking the medicine.

4. The infusion rate should be strictly controlled during treatment. Within the first 10 minutes of the infusion of paclitaxel, the drip rate can be maintained at 10gtt/min. If the patient has no discomfort, the drip rate can be adjusted to 45gtt/min, and the drip should generally be completed within 3 hours.

5. Closely observe changes in the patient's vital signs. Before and during the infusion, it is best to monitor blood pressure, pulse and respiration every 30 minutes. Within 15 minutes of the start of the infusion, the patient should be closely observed and asked if he or she feels any discomfort, so as to detect and prevent allergic reactions in a timely manner.

6. At the end of the infusion, the patient's blood pressure should be measured, and the infusion tube should be removed after the patient has no abnormal reaction. The patient's vital signs should continue to be closely observed within 24 hours after the needle is removed. If the patient develops facial flushing or mild rash, the medication should be stopped immediately.